BA.3.2 COVID Variant: CDC Report on Spread, Immune Evasion & Surveillance

The Centers for Disease Control and Prevention (CDC) is tracking a newly emerging variant of SARS-CoV-2, designated BA.3.2, which has been detected globally and is now showing up in U.S. Wastewater surveillance and traveler screenings. This ongoing monitoring, detailed in a recent Morbidity and Mortality Weekly Report (MMWR), highlights the importance of continued genomic surveillance as the virus continues to evolve.

First identified in South Africa in November 2024, BA.3.2 has since been reported in 23 countries, with a noticeable increase in detections beginning in September 2025. The CDC’s early detection in the United States – through analysis of samples from travelers, airplane wastewater, clinical specimens, and wastewater surveillance across 25 states – demonstrates the effectiveness of current monitoring systems.

Variant Characteristics and Immune Evasion

What sets BA.3.2 apart is its significant divergence from previously dominant strains like JN.1 and LP.8.1. The variant carries approximately 70-75 substitutions and deletions in the spike protein, the part of the virus that binds to human cells and is targeted by vaccines and prior immunity. This substantial genetic shift raises concerns about potential immune evasion – the ability of the virus to bypass protection from previous infections or vaccinations. The CDC report details these genetic characteristics and their potential implications.

However, it’s important to note that, as of the data collected through February 11, 2026, BA.3.2 hadn’t rapidly overtaken other circulating variants. This suggests that even as the immune evasion potential is a factor to watch, it hasn’t yet translated into a dominant strain. The CDC’s primary message remains focused on continued genomic surveillance to track the variant’s evolution and impact.

How Surveillance Works: A Multi-Layered Approach

The CDC’s detection of BA.3.2 relies on a multi-faceted approach to genomic surveillance. This includes analyzing sequences uploaded to open-access databases like the National Center for Biotechnology Information (NCBI) and the Global Initiative on Sharing All Influenza Data (GISAID), as well as monitoring preprint databases, media reports, and online platforms for emerging signals. News-Medical provides a concise overview of this tracking process.

Within the U.S., the CDC integrates data from three key sources: traveler-based genomic surveillance (TGS), national SARS-CoV-2 genomic surveillance, and the national wastewater surveillance system (NWSS). TGS analyzes samples from airplane wastewater and travelers’ nasal swabs, while NWSS monitors approximately 1,300 wastewater sites across the country to detect the presence of the virus and identify circulating variants. The National SARS-CoV-2 Strain Surveillance (NS3) program combines sequencing data from various sources to track variant proportions over time.

U.S. Findings: From Travelers to Wastewater

The first U.S. Detection of BA.3.2 occurred on June 27, 2025, through the TGS program, identifying the variant in a traveler arriving from the Netherlands. Wastewater surveillance in Rhode Island picked up the signal on November 11, 2025. Clinical samples, collected between December 4, 2025, and January 4, 2026, confirmed cases in a young child and two older adults with underlying health conditions – all of whom survived.

As of February 11, 2026, BA.3.2 had been identified in five respiratory samples, four traveler nasal swabs, three airplane sewage samples, and 132 wastewater surveillance samples from 25 states. Further analysis revealed two subvariants, BA.3.2.1 and BA.3.2.2, indicating ongoing viral evolution. More recent data, through March 12, 2026, shows an increase in detections – six travelers, 29 patients, three airplane sewage samples, and 260 wastewater samples from 29 states and Puerto Rico – with prevalence rising from 0.19% to 0.55% of sequenced samples. USA Today reports on the spread of this variant.

What Does This Mean for Public Health?

The emergence and global spread of BA.3.2 underscore the continued evolution of SARS-CoV-2 and the critical need for robust genomic surveillance. While laboratory studies suggest the variant can evade antibodies generated by prior infection or vaccination, clinical data to date haven’t indicated a significant increase in disease severity. All patients identified in the U.S. Have survived.

The success of wastewater and traveler-based surveillance in detecting BA.3.2 before widespread clinical cases highlights the value of these proactive monitoring strategies. Although BA.3.2 hasn’t yet turn into the dominant strain, its continued circulation and ongoing mutations warrant close attention. WSB-TV offers a general overview of the current COVID-19 variant situation.

Sustained genomic surveillance, combined with ongoing studies evaluating the effectiveness of vaccines and antiviral treatments, will be essential for guiding public health strategies and informing future vaccine composition decisions. The CDC continues to monitor BA.3.2 and will provide updates as recent information becomes available.

Looking Ahead: The CDC emphasizes that continued vigilance and data collection are key. This includes ongoing wastewater monitoring, genomic sequencing of clinical and travel samples, and collaboration with international partners to track the global spread of BA.3.2 and other emerging variants. Public health recommendations will be updated as needed based on the evolving understanding of the virus and its impact.